JANUX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57 USD | +1.64% |
|
+14.50% | +431.22% |
| 04-16 | JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target | MT |
| 04-10 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Sales 2024 * | 3.15M 4.34M | Sales 2025 * | 2.47M 3.4M | Capitalization | 2.91B 4B |
|---|---|---|---|---|---|
| Net income 2024 * | -72M -99.15M | Net income 2025 * | -95M -131M | EV / Sales 2024 * | 922 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1,176 x |
| P/E ratio 2024 * |
-41.5
x | P/E ratio 2025 * |
-34.2
x | Employees | 64 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.64% | ||
| 1 week | +14.50% | ||
| Current month | +51.39% | ||
| 1 month | +51.23% | ||
| 3 months | +522.27% | ||
| 6 months | +829.85% | ||
| Current year | +431.22% |
1 week
45.68
61.00
1 month
34.6361.00
Current year
7.7961.00
1 year
5.6561.00
3 years
5.6561.00
5 years
5.6561.00
10 years
5.6561.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 17-05-31 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 21-03-17 |
Jay Lichter
CHM | Chairman | 62 | 17-05-31 |
| Director/Board Member | 68 | 21-09-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +4.89% | - | |
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 57 | +1.64% | 653 425 |
| 24-04-29 | 56.08 | +18.34% | 1,537,542 |
| 24-04-26 | 47.39 | +0.62% | 573,989 |
| 24-04-25 | 47.1 | -2.30% | 555,331 |
| 24-04-24 | 48.21 | -3.15% | 580,167 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm
More quotes
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
56.08
USD
Average target price
58.29
USD
Spread / Average Target
+3.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +431.22% | 2.9B | |
| +0.17% | 42.86B | |
| +10.92% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +5.23% | 25.15B | |
| -24.79% | 18.63B | |
| +26.69% | 12.37B | |
| -3.13% | 11.92B | |
| +6.57% | 11.21B |
- Stock Market
- Equities
- JANX Stock
